Examples of using Data from this study in English and their translations into Greek
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Official/political
-
Computer
Table 1 summarizes efficacy data from this study.
Data from this study had already been used in the authorisation of Tivicay.
Recently, a team from the Sahlgrenska Academy of the University of Gothenburg in Sweden used data from this study to look at the links between psychological well-being and weight in children.
Safety data from this study was in line with previous known safety profile of linagliptin.
Identify the main conclusion(outcome of the study), supports for this main conclusion(data from this study or previous research) and the implication(e.g. need for further study or impact on society).
Overall the data from this study were not considered adequate for the purpose of deriving a milk withdrawal period.
Data from this study showed that meropenem was highly effective in the treatment of bacterial gynaecological infections.
The change was dose dependent. The safety data from this study in patients aged 6 to< 18 years appeared generally similar to that observed in adults.
Full data from this study will be made available through scientific disclosure at upcoming congresses and publications.
The four-year safety data from this study are consistent with the previously reported safety profile of SPRYCEL 100 mg once daily.
The data from this study showed that the effect of ertugliflozin reduces when the kidneys do not work properly.
Municipal foresters can use data from this study to see how their trees compare to other cities in their climate zone or in the state," McPherson said.
Safety data from this study seem to be in line with the safety profile of imatinib in Ph+ ALL patients.
The data from this study indicates that the prevalence of gestational diabetes is between 4.6 and 9.2 percent of all pregnancies.
Full data from this study will be made available through scientific disclosure at upcoming congresses and peer-reviewed publications.
Data from this study suggest that one important factor is the blood flow to the ovarian follicles in which the eggs develop.
The safety data from this study in patients aged 6 to< 18 years appeared generally similar to that observed in adults.
The data from this study demonstrate that the two prophylactic dosing regimens are comparable in terms of reduction of bleeding rate.
Data from this study showed that qualifying relapses were reduced in RMS patients aged below and above 45.
There are limited data from this study in patients with Child Pugh B liver impairment and only one patient with Child Pugh C had been included.
Data from this study collected until week 96 showed that this effect was maintained over time.
Efficacy data from this study suggests that clinical benefit provided at week 16 was sustained through week 52.
The data from this study provides a strong case for routine assessment of vitamin B12 levels during long term treatment with metformin.
The data from this study shows that the more consistent the owner's behaviors are the better the dogs' obedience behaviors are regardless of their size.
Preliminary data from this study after one year show that Spherox improved by 22 points the outcome score and was as effective as microfracture.
Data from this study demonstrated a significant advantage for intravenous Ibandronate 6 mg over placebo in the reduction in SREs measured by the time-adjusted SMPR(p=0.004).
Data from this study demonstrated a significant advantage for intravenous Bondronat 6 mg over placebo in the reduction in SREs measured by the time-adjusted SMPR(p=0.004).
The data from this study indicate that bosutinib does not prolong the QTc in healthy subjects at the dose of 500 mg daily with food, and under conditions that give rise to supratherapeutic plasma concentrations.
Data from this study demonstrated a significant advantage for intravenous Ibandronate 6 mg over placebo in the reduction in SREs measured by the time-adjusted SMPR(p=0.004).
Hence, data from this study could not be extrapolated to the only product containing the excipient polyethylene glycol 400(Tilocen, marketing authorisation holder: A. Nikolakopoulos S. A), for the reason mentioned above.